[Immunotherapy of prostate cancer].
In recent years immunotherapy of prostate cancer has developed into an innovative field of investigation. Nevertheless, in contrast to some other human tumors in which immunotherapy has been demonstrated to be effective, no breakthrough has been achieved with respect to a successful clinical application of this modality to prostate cancer. So far studies focus either on immunologically specific or nonspecific treatment concepts. Based on this, the modes of action of monoclonal antibodies, adoptive immunotherapy techniques, tumor cell vaccination, various biological response modifiers and substances with immunological as well as tumoritoxic/-static attributes are studied. Not all of the results obtained so far offer new insights into tumor biology. Ongoing studies in all fields continue to pursue immunological mechanisms for effective systemic therapy of prostate cancer. Major impulses may be seen only via immunologically specific concepts. Through these, new therapeutic modalities for patients with advanced prostate cancer may be developed which are more efficacious than androgen ablation.
Schulze
H
H
Urologische Klinik, Ruhr-Universität Bochum, Marienhospital Herne.
Sommerfeld
H J
HJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003374:Coumarins / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods; D016219:Immunotherapy, Adoptive / Q000379:methods; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*; D013498:Suramin / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D003374:Coumarins; D013498:Suramin; C030123:coumarin
Immuntherapie beim Prostatakarzinom.